# Statin use is safe and does not impact prognosis in patient with de novo follicular lymphoma treated with immunochemotherapy: An exploratory analysis of the PRIMA cohort study

Emmanuel Bachy, Jane A. Estell, Eric van De Neste, Reda Bouabdallah, Joan Bargay, Alain Delmer, Bénédicte Gelas-Dore, Maria Gomes Da Silva, Olivier Fitoussi, David Belada, et al.

**Statin use is safe and does not impact prognosis in patient with de novo follicular lymphoma treated with immunochemotherapy: an exploratory analysis of the PRIMA cohort study**

Emmanuel Bachy[1], Jane A Estell[2], Eric Van de Neste[3], Réda Bouabdallah[4], Joan Bargay[5], Alain Delmer[6], Bénédicte Gelas-Dore[7], Maria Gomes da Silva[8], Olivier Fitoussi[9], David Belada[10], Hervé Maisonneuve[11], Tanin Intragumtornchai[12], Thierry Lamy[13], Peggy Dartigues[14], John Francis Seymour[15] and Gilles Salles[1].

[1]Hôpital Lyon Sud and Université Claude Bernard, Pierre-Bénite, France; [2]Concord Hospital, Concord, NSW, Australia ; [3]Hematology Department, Cliniques universitaires UCL Saint-Luc, Brussels, Belgium ; [4]Institut Paoli Calmettes, Marseille, France ; [5]Hospital Son Llàtzer, Palma de Mallorca, Spain ; [6]CHU de Reims, Reims, France ; [7]Deparment of Biostatistics, Lysarc, Lyon, France ; [8]Portuguese Institute of Oncology, Lisbon, Portugal ; [9]Polyclinique Bordeaux Nord Aquitaine, Bordeaux, France ; [10]University Hospital Hradec Kràlové, Prague, Czech Republic; [11]Centre Hospitalier de la Roche sur Yon, France; [12]Chulalongkorn University, Bangkok, Thailand ; [13]Centre hospitalier Pontchaillou, Rennes, France ; [14]Institut Gustave Roussy, Villejuif, France ; [15]Peter MacCallum Cancer Centre and University of Melbourne, Melbourne, VIC, Australia.

**Running head** : statin use in follicular lymphoma

**Corresponding author:** Dr Emmanuel Bachy, M.D. Ph.D., Center for Cancer Research, National Institute of Health, National Cancer Institute, Building 10, Room 5A02, Bethesda, MD 20892. Phone : +1-(202)-600-1968. Email : emmanuel.bachy@nih.gov

Presented in part at the 54th Annual Meeting and Exposition of the American Society of Hematology, Atlanta, GA, December 8-11 2012

**ABSTRACT**

An adverse prognostic impact of statin use in lymphoma was first suspected from *in vitro* data showing an impairment of anti-CD20 antibody binding. However, further clinical studies suggested an improved outcome associated with their use in hematological malignancies. In particular, a survival benefit was reported for patients with follicular lymphoma on statins. Our objective was to assess the outcome of follicular lymphoma patients treated in the PRIMA study with immunochemotherapy according to the use of statins. Among the 1217 patients enrolled in the PRIMA study, 1135 were included in the present study. Concomitant treatments at registration were available for all patients. Among those 1135 patients, 119 were on statins (10.4%) at diagnosis. Adverse events frequencies, event-free survival (EFS), time to next lymphoma treatment (TTNLT), time to next chemotherapy (TTNCT) and overall survival (OS) were evaluated according to the use of statins. The rates of overall and specific cardiovascular adverse events between the 2 groups of patients were comparable both during induction and maintenance. Outcome in terms of response rates or EFS, TTNLT, TTNCT and OS were similar regardless of the use of statins (*P*=.57, *P*=.85, *P*=.30 and *P*=.43 respectively) in univariate analysis and after further adjustments for potential confounding factors in multivariate analysis. In conclusion, statin use does not impact the prognosis of patients with follicular lymphoma treated with immunochemotherapy.

## INTRODUCTION

Follicular lymphoma (FL) is the second most common subtype of non-Hodgkin lymphoma (NHL). Most patients have disseminated disease at presentation, but immediate treatment with immunotherapy or immunochemotherapy is not always required since the disease usually follows an indolent course.[1] When treatment is initiated, FL is characterized by a high initial response rate but in most patients the disease will ultimately relapse, although recent data suggest that prolonged PFS can be achieved with first line treatment.[2,3] However, subsequent remissions are usually of sequentially shorter durations.[4] After decades of disappointing results, overall survival has recently improved since the addition of rituximab to the therapeutic armamentarium in FL.[5-11] However, no cure of the disease is suggested in recent trials or long-term follow-up studies of conventional chemotherapy despite the broad use of anti-CD20 containing regimen.[12,13] New treatment strategies are therefore needed to improve the prognosis of patients with FL, especially those exhibiting adverse prognostic characteristics at diagnosis. To this end, new monoclonal antibodies and/or combined targeted therapies are currently in development or evaluated within clinical trials with promising results.[14,15]

Little is known about the possible beneficial effect of concomitant non-antineoplastic medication when immunochemotherapy is utilized. In this regard, conflicting results have been published to date concerning the impact of statin use on the prognosis of patients with NHL treated with a rituximab-containing first-line regimen. Accumulating evidence suggests that statin use has a potential antitumor effect[16] in addition to their known ability to improve dyslipidemia and reduce cardiovascular morbidity and mortality.[17] Recent studies suggest reduced cancer-specific mortality after prostate cancer diagnosis among statin users.[16,18] Paradoxically, an adverse prognostic impact of statin use in lymphoma was suspected from *in vitro* data showing an impairment of anti-CD20 antibody binding due to changes in

conformational epitopes of the molecule by an outer plasma membrane cholesterol-dependent mechanism. As a result, statins were found to decrease anti-CD20 induced complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity.[19,20]

Several groups worldwide attempted to assess the outcome of patients concomitantly receiving statins and rituximab for NHL. No detrimental effect was observed across studies for patients with diffuse large B-cell lymphoma treated upfront with R-CHOP or R-CHOP-like regimens[21,22] or for patients with chronic lymphoid leukemia (CLL) either during "watchful waiting" or treatment with a rituximab-containing therapy.[23] However, an unexpected prolongation of event-free survival (EFS) was observed for patients with FL receiving statins in a study from Nowakowski et al.[21] Several caveats of the study precluded definitive conclusions to be drawn; including treatment heterogeneity, the enrollment of patients who did not receive rituximab, the retrospective assessment of statin use through medical charts and the consideration of EFS as the primary endpoint without specific evaluation of overall survival (OS).[21] Notably, another recent study demonstrated a favorable outcome for patients with relapsed/refractory CLL both on statins and aspirin and treated by a rituximab-fludarabine-cyclophosphamide (FCR) regimen.[23] The impact of statin use on the prognosis of patients with FL therefore requires further investigation.

The PRIMA study is an international open-label phase III trial in which 1217 patients with de novo FL were enrolled. The trial demonstrated a favorable outcome in terms of EFS for patients receiving a 2-year maintenance treatment with rituximab on a bi-monthly basis following an induction immunochemotherapy regimen.[24] Since all concomitant medications were registered at enrollment, the study provided the opportunity to specifically analyze the effect of statin use during initial treatment on outcome.

Our objective is to determine whether the outcome of follicular lymphoma patients treated in the PRIMA study with immunochemotherapy was favorably effected by the antineoplastic

action of statins or detrimentally effected by the potential adverse action of statins on anti

CD20 binding.

## PATIENTS AND METHODS

### Study Population

The randomized, open-label PRIMA study enrolled 1217 patients with *de novo* FL from 223 centers in 25 countries. Patients achieving at least a partial response following frontline therapy with physician-selected R-CHOP, R-CVP or R-FCM were randomized between 2-years rituximab maintenance (every 8 weeks) or observation.[24]

Patients with grade 1, 2, or 3a FL were eligible for induction if they were older than 18 years and presented with at least one high burden criterion among the following: any nodal or extranodal tumor mass with a diameter greater than 7 cm, involvement of three nodal sites with a diameter greater than 3 cm, systemic symptoms, substantial splenic enlargement, any compression syndrome (ureteral, orbital, gastrointestinal), or serous effusion (irrespective of cell content), elevated serum levels of lactic dehydrogenase (LDH) or $\beta_2$-microglobulin (above upper normal limit).

Patients with responding disease (either complete or partial) were randomly assigned in a 1:1 ratio to receive 2 years of rituximab maintenance therapy ($375mg/m^2$ IV every 8 weeks) or observation (see flowchart in supplementary figure 1) but all enrolled patients before the induction phase were considered in the present study.

The PRIMA study was registered on the National Institute of Health website, number NCT00140582.

The protocol was approved by local or national ethics committees according to the laws of each country and the study was in accordance with the declaration of Helsinki. All patients gave written informed consent before registration.

The trial demonstrated a significant improvement of the primary endpoint (i.e. progression-free survival (PFS) from randomization) in the rituximab maintenance arm.[24] 3-year PFS was

74.9% (95% CI 70.9-78.9) in the rituximab maintenance group and 57.6% (95% CI 53.2-62.0) in the observation group (stratified log rank, *P*<.0001).

### Statin Exposure

All concomitant treatments at study enrollment, including the use of statins, were prospectively collected. Concomitant treatments at therapy initiation were registered only if continuing at least up to 4 weeks during the trial.

### Statistical analysis

Statistical analyses were performed using SAS version 9.2 for PC (SAS Institute, Cary, NC). A *P* value <.05 was considered as statistically significant. All statistical tests were 2-sided. Baseline demographic characteristics between patients on statins and those not on statins were compared with the use of a Chi-square test. In the original PRIMA study publication,[24] all time-to-event evaluations were calculated from the date of randomization to the date of the event considered. Since effect of statins use during induction therapy was of interest in the present study, all time-to-event endpoints presented here were calculated from the date of the first induction course with R-CHOP, R-CVP or R-FCM. EFS, time-to-next lymphoma treatment (TTNLT) and time-to-next chemotherapy (TTNCT) were defined according to IWG 1999.[25] Specifically, EFS was defined as the interval between the date of induction to the date of first documented disease progression, relapse, initiation of a new anti-lymphoma treatment or death from any cause. EFS was used as an endpoint instead of PFS so that results could be compared to previously published data concerning the prognostic impact of statins in patients with FL.[21] Patients with ongoing responding disease and patients who were lost to follow-up were censored at their last tumor assessment date.

All endpoints were examined in univariate and multivariate analyses. Three different multivariate hazard ratio Cox regression models were used to assess the prognostic value of statin use after adjustment for potentially confounding factors.

A first model included imbalanced prognostic variables between statin patients and non-statin patients with a level of significance set up at 0.1 (as listed in Table 1) except FLIPI score. A second model was built considering the actual FLIPI score instead of its individual components included in the first multivariate model (i.e. age, stage and LDH). Finally, a third model using stepwise regression comprising alternating forward and backward elimination steps was used to find the most parsimonious set of covariates with independent statistical significance among the following: statin use, age, sex, stage, performance status, B symptoms, $\beta_2$-microglobulin level, LDH, hemoglobin, bone marrow involvement, induction treatment (continuous variables incorporated into the model were dichotomized as presented in Table 1). Given a proportion of patients did not achieve at least PR to induction and therefore were not randomized to the maintenance/observation phase, maintenance as such could not be included as a variable in the models. Level for entry into the model was set at 0.2 with a stay level of 0.05. Importantly, statin use was forced into the model since it was the variable of interest in the study.

## RESULTS

### *Patient Characteristics at Baseline*

Among the 1217 patients enrolled in the PRIMA study, 1135 were included in the present study. Fifteen were excluded because of premature sites closure, 58 because of other lymphoma subtype diagnosis at central histological review and 9 because of consent withdrawal before any treatment (Supplementary Figure S1). Concomitant treatments at registration were available for all patients. Among those 1135 patients, 119 were on statins (10.5%) at diagnosis. Patient characteristics according to statin use are presented in Table 1. Details on statin subtypes for the study population are provided in Supplementary Table S1 and a flowchart according to statin use is presented in Supplementary Figure S1.

The use of any statin was associated with an older age at registration and, partly as a consequence, to a higher FLIPI risk score. Median age for the cohort was 57 years (range, 22-87). Overall 50 of 733 (6.8%) of those age ≤60 used statins, whereas 69 of 402 (17.2%) of those age >60 (*P*<.001). In the high FLIPI risk category, 14% of patients were on statins compared to 5% in the low risk category (*P*<.001). Male sex and disseminated disease was also overrepresented among statin users, although not significantly (*P*=.076 and *P*=.074 respectively). LDH was more frequently above the upper normal limit (*P*=.03). No other differences were observed with regards to demographic data, induction treatment or maintenance allocation according to statin use (Table 1 and Supplementary Table S2).

### *Treatment Toxicities According to Statin Use*

The rate of adverse events (AE) between the 2 groups of patients was comparable, in terms of both the incidence of AE of any grade or of grade 3/4. This was observed when analyzing the entire treatment schedule (induction and maintenance) or just the induction phase using R-CHOP or R-CVP regimens (Supplementary Table S3). No difference in terms of specific

cardiovascular AE were observed (Supplementary Table S4). Three deaths potentially due to cardiovascular events were observed for patients without statin (reported in flow chart as cardiorespiratory arrest for one patient and sudden death for two patients) versus none for patients prescribed statins. No difference in premature withdrawal during induction or maintenance was associated with statin use (data not shown). No difference was observed between second cancer incidences between the 2 groups of patients as well (Supplementary Table S5).

### *Disease Response Rate According to Statin Use*

No differences in overall response rate to induction regimen, nor in the quality of the response (CR/CRu *versus* PR *versus* others) was noted (*P*=.52) (Table 2). No further differences were found at the end of the maintenance period (*P*=.67). Subgroup analyses by maintenance arm displayed similar response rates either for patients in the observation arm compared to the rituximab treatment arm (data not shown).

### *Survival According to Statin Use*

Outcome in terms of EFS, TTNLT, TTNCT and OS were similar regardless of the use of statins (*P*=.57, *P*=.85, *P*=.30 and *P*=.43 respectively) in univariate analysis (Fig 1A-D). Importantly, further adjustments for potential confounding factors such as age, sex, stage or LDH in the first multivariate model, sex and FLIPI in the second model or with the use of a forward/backward selection process in the third model did not reveal any potential effect of statin use on EFS or OS (Table 3). No significant effect of statins after further adjustment on maintenance arm was found (data not shown).

11

## DISCUSSION

Biologically, statins inhibit 3-hydroxy-3-methylglutaryl-coenzyme A reductase and impair cholesterol synthesis through inhibiting the mevalonate pathway. Such inhibition is thought to have antitumor effect by interfering with lipid cell-membrane formation and protein prenylation. Several oncoproteins such as Ras undergo prenylation, thus farnesyl transferase inhibitors such as statins might impair tumor growth.[26] Accumulating evidence suggests that statins have a potential antitumor effect[16] in addition to their known ability to improve dyslipidemia and reduce cardiovascular morbidity and mortality.[17] Notably, recent studies suggest a reduced cancer-specific mortality after prostate cancer diagnosis among statin users.[16,18] In lymphoma, statins were recently shown to induce apoptosis by promoting ROS generation and Akt, Erk and p38 signalling pathway regulation.[27] Malenda et al also demonstrated that HMG-CoA reductase inhibitors impair glucose uptake in tumor cells possibly by inhibiting a putative cholesterol-binding motif in the juxtamembrane fragment of glucose transporter 1 (GLUT-1).[28]

In patients treated on the PRIMA study there was no significant effect of statins on response rate or survival, even after adjustment for potential confounding factors (especially age and gender), was observed. 10.5% of patients were on statins at enrollment consistent with the estimated one in ten adults in the general population among US adults.[29] Importantly, all patients on this prospective randomized trial presented with stage II, III or IV disease with at least one high tumor burden criterion and required immediate treatment for FL. They were homogeneously treated with a rituximab-containing immuno-chemotherapy regimen at induction (mainly R-CHOP or R-CVP therapy) and, in case of response, were further randomized between observation and rituximab maintenance for 2 years. Those results are in accordance with findings by Ennishi et al. in diffuse large B-cell lymphoma where no

12

detrimental effect was observed among patients on statins.[30] They also confirm that no

treatment interruption is required for statins at lymphoma diagnosis in FL subtype.

In 2009, a report from the Mayo Clinic, Rochester, described a benefit of statin therapy on FL

outcome, as assessed by EFS based on a registry data and prospective observation (N=289).[21]

Notably, 35% of patients in the present cohort were older than 60 years compared to 54% in

the FL subpopulation of the aforementioned study. As a result, at least in part, 21% of patients

were on statins compared to 10% in our study. Furthermore, patients had undergone

heterogeneous treatments; 40% of patients with FL were in a "watch and wait" approach, and

only 41% received a rituximab-containing therapy. Although all patients in this study seem to

benefit from statin use, a more significant impact was observed among patients on

observation. Hence, the prolonged EFS observed with statin use was consistent across patients

treated with rituximab-based regimen or whose initial therapy was observation only but

within a thinner range of confidence interval for the later (95% CI 0.14-1.07 versus 0.17-

0.84). This therefore raises the question as to whether the known treatment advantage of

immunochemotherapy in all patients in the PRIMA study negated any potential advantageous

effect of statin use.

As with other subtypes of NHL, the use of statins in patients with FL in the rituximab era

appeared safe and was not associated with an inferior outcome as initially suggested by *in

vitro* experiments.

13

## REFERENCES

1. Solal-Celigny P, Bellei M, Marcheselli L, et al: Watchful waiting in low-tumor burden follicular lymphoma in the rituximab era: results of an F2-study database. J Clin Oncol 30:3848-53, 2012

2. Horning SJ: Natural history of and therapy for the indolent non-Hodgkin's lymphomas. Semin Oncol 20:75-88, 1993

3. Press OW, Unger JM, Rimsza LM, et al: Phase III randomized intergroup trial of CHOP plus rituximab compared with CHOP chemotherapy plus (131)iodine-tositumomab for previously untreated follicular non-Hodgkin lymphoma: SWOG S0016. J Clin Oncol 31:314-20, 2013

4. Gallagher CJ, Gregory WM, Jones AE, et al: Follicular lymphoma: prognostic factors for response and survival. J Clin Oncol 4:1470-80, 1986

5. Hainsworth JD, Burris HA, 3rd, Morrissey LH, et al: Rituximab monoclonal antibody as initial systemic therapy for patients with low-grade non-Hodgkin lymphoma. Blood 95:3052-6, 2000

6. Herold M, Haas A, Srock S, et al: Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study. J Clin Oncol 25:1986-92, 2007

7. Hiddemann W, Kneba M, Dreyling M, et al: Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 106:3725-32, 2005

8.      Liu Q, Fayad L, Cabanillas F, et al: Improvement of overall and failure-free survival in stage IV follicular lymphoma: 25 years of treatment experience at The University of Texas M.D. Anderson Cancer Center. J Clin Oncol 24:1582-9, 2006

9.      Salles G, Mounier N, de Guibert S, et al: Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study. Blood 112:4824-31, 2008

10.      Swenson WT, Wooldridge JE, Lynch CF, et al: Improved survival of follicular lymphoma patients in the United States. J Clin Oncol 23:5019-26, 2005

11.      Hochster H, Weller E, Gascoyne RD, et al: Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: results of the randomized phase III ECOG1496 Study. J Clin Oncol 27:1607-14, 2009

12.      Bachy E, Houot R, Morschhauser F, et al: Long-term follow up of the FL2000 study comparing CHVP-interferon to CHVP-interferon plus rituximab in follicular lymphoma. Haematologica 98:1107-14, 2013

13.      Bachy E, Brice P, Delarue R, et al: Long-term follow-up of patients with newly diagnosed follicular lymphoma in the prerituximab era: effect of response quality on survival--A study from the groupe d'etude des lymphomes de l'adulte. J Clin Oncol 28:822-9, 2010

14.      Gopal AK, Kahl BS, de Vos S, et al: PI3Kdelta Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma. N Engl J Med, 2014

15.      Radford J, Davies A, Cartron G, et al: Obinutuzumab (GA101) plus CHOP or FC in relapsed/refractory follicular lymphoma: results of the GAUDI study (BO21000). Blood 122:1137-43, 2013

16.      Nielsen SF, Nordestgaard BG, Bojesen SE: Statin use and reduced cancer-related mortality. N Engl J Med 367:1792-802, 2012

17. Eisenberg DA: Cholesterol lowering in the management of coronary artery disease: the clinical implications of recent trials. Am J Med 104:2S-5S, 1998

18. Yu O, Eberg M, Benayoun S, et al: Use of statins and the risk of death in patients with prostate cancer. J Clin Oncol 32:5-11, 2014

19. Winiarska M, Bil J, Wilczek E, et al: Statins impair antitumor effects of rituximab by inducing conformational changes of CD20. PLoS Med 5:e64, 2008

20. Winiarska M, Nowis D, Bil J, et al: Prenyltransferases regulate CD20 protein levels and influence anti-CD20 monoclonal antibody-mediated activation of complement-dependent cytotoxicity. J Biol Chem 287:31983-93, 2012

21. Nowakowski GS, Maurer MJ, Habermann TM, et al: Statin use and prognosis in patients with diffuse large B-cell lymphoma and follicular lymphoma in the rituximab era. J Clin Oncol 28:412-7, 2010

22. Samaras P, Heider H, Haile SR, et al: Concomitant statin use does not impair the clinical outcome of patients with diffuse large B cell lymphoma treated with rituximab-CHOP. Ann Hematol 89:783-7, 2010

23. Chae YK, Trinh L, Jain P, et al: Statin and aspirin use is associated with improved outcome of FCR therapy in relapsed/refractory chronic lymphocytic leukemia. Blood 123:1424-6, 2014

24. Salles G, Seymour JF, Offner F, et al: Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet 377:42-51, 2011

25. Cheson BD, Pfistner B, Juweid ME, et al: Revised response criteria for malignant lymphoma. J Clin Oncol 25:579-86, 2007

26. Jakobisiak M, Golab J: Potential antitumor effects of statins (Review). Int J Oncol 23:1055-69, 2003

27.    Qi XF, Zheng L, Lee KJ, et al: HMG-CoA reductase inhibitors induce apoptosis of lymphoma cells by promoting ROS generation and regulating Akt, Erk and p38 signals via suppression of mevalonate pathway. Cell Death Dis 4:e518, 2013

28.    Malenda A, Skrobanska A, Issat T, et al: Statins impair glucose uptake in tumor cells. Neoplasia 14:311-23, 2012

29.    Mann D, Reynolds K, Smith D, et al: Trends in statin use and low-density lipoprotein cholesterol levels among US adults: impact of the 2001 National Cholesterol Education Program guidelines. Ann Pharmacother 42:1208-15, 2008

30.    Ennishi D, Asai H, Maeda Y, et al: Statin-independent prognosis of patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP therapy. Ann Oncol 21:1217-21, 2010

17

Figure 1. Outcome according to statin use. A. Event-free survival; B. Time to next lymphoma treatment; C. Time to next chemotherapy; D. Overall survival.
193x146mm (300 x 300 DPI)

**Table 1. Patient characteristics according to statin use**

| | | N (%) | | |
|---|---|---|---|---|
| | **Missing Data (N)** | **No Statin use (N=1016)** | **Statin use (N=119)** | **P** |
| **Age, yrs** | 0 | | | **<.001** |
| ≤60 | | 683 (93) | 50 (7) | |
| >60 | | 333 (83) | 69 (17) | |
| **Sex** | 0 | | | .076 |
| Female | | 497 (91) | 48 (9) | |
| Male | | 519 (88) | 71 (12) | |
| **ECOG** | 0 | | | .73 |
| 0 | | 648 (90) | 74 (10) | |
| 1-2 | | 368 (89) | 45 (11) | |
| **B symptoms** | 0 | | | .20 |
| no | | 685 (89) | 87 (11) | |
| yes | | 331 (91) | 32 (9) | |
| **Stage** | 0 | | | .074 |
| I-II | | 103 (94) | 6 (6) | |
| III-IV | | 913 (89) | 113 (11) | |
| **Nodal sites involvement, N** | 0 | | | .43 |
| ≤4 | | 448 (90) | 48 (10) | |
| >4 | | 568 (89) | 71 (11) | |
| **Bone marrow involvement** | 34 | | | .35 |
| no | | 422 (91) | 44 (9) | |
| yes | | 564 (89) | 71 (11) | |
| **Extranodal sites involvement, N** | 0 | | | .14 |
| ≤2 | | 914 (89) | 112 (11) | |
| >2 | | 102 (94) | 7 (6) | |
| **LDH** | 5 | | | **.030** |
| ≤UNL | | 684 (91) | 68 (9) | |
| >UNL | | 328 (87) | 50 (13) | |
| **Hemoglobin, g/dL** | 0 | | | .35 |
| ≥12 | | 809 (89) | 99 (11) | |
| <12 | | 207 (91) | 20 (9) | |
| **ß2-microglobulin, mg/L** | 85 | | | .47 |
| ≤3 | | 640 (90) | 69 (10) | |
| >3 | | 303 (89) | 38 (11) | |
| **FLIPI** | 2 | | | **.001** |
| Low (0-1 factor) | | 227 (95) | 12 (5) | |
| Intermediate (2 factors) | | 366 (90) | 39 (10) | |
| High (≥3 factors) | | 422 (86) | 67 (14) | |
| **Induction therapy** | 0 | | | |
| R-CHOP | | 756 (90) | 84 (10) | .064 |
| R-CVP | | 219 (87) | 34 (13) | |
| R-FCM | | 41 (98) | 1 (2) | |

*Abbreviations: yrs, years; ECOG, eastern cooperative oncology group; LDH, lactate dehydrogenase; UNL, upper normal limit; FLIPI, follicular lymphoma prognostic index); R-CHOP, rituximab cyclophosphamide doxorubicin vincristine prednisone; R-CVP, rituximab cyclophosphamide vincristine prednisone; R-FCM, rituximab fludarabine cyclophosphamide and mitoxantrone.*

**Table 2. Adverse events during treatment (induction and maintenance) or induction only according to statin use**

| | N (%) | | |
| --- | --- | --- | --- |
| | No Statin use (N=1016) | Statin use (N=119) | *P* |
| **At least one AE during treatment** | | | |
|    No | 10 (1.0) | 1 (1.9) | .87 |
|    Yes | 1006 (99.0) | 118 (99.2) | |
| **Intensity during treatment[1]** | | | |
|    Grade 1, 2 | 190 (18.7) | 27 (22.7) | .18 |
|    Grade 3, 4 | 796 (78.3) | 89 (74.8) | |
| **At least one AE during induction** | | | |
|    No | 10 (1.0) | 2 (1.7) | .48 |
|    Yes | 1006 (99.0) | 117 (98.3) | |
| **Intensity during induction[1]** | | | |
|    Grade 1, 2 | 222 (21.9) | 31 (26.1) | .24 |
|    Grade 3, 4 | 772 (76.0) | 85 (71.4) | |

*Abbreviations: AE, adverse event.*
*[1]Sum of percents might not equal 100 since unknown grade and grade 5 AE are not taken into account.*

### Table 3. Multivariate Cox analysis models

#### Model 1[1]

| | EFS | | | OS | | |
|---|---|---|---|---|---|---|
| | HR | 95% CI | *P* | HR | 95% CI | *P* |
| Age, yrs | | | | | | |
| >60 (*v* ≤60) | 0.99 | 0.82-1.18 | .91 | 1.91 | 1.31-2.78 | <.001 |
| Sex | | | | | | |
| Male (*v* female) | 1.29 | 1.08-1.54 | .003 | 1.51 | 1.03-2.21 | .032 |
| Stage | | | | | | |
| III-IV (*v* I-II) | 1.64 | 1.16-2.32 | .004 | 2.10 | 0.85-5.15 | .10 |
| LDH | | | | | | |
| >UNL (*v* ≤UNL) | 1.37 | 1.15-1.63 | <.001 | 2.24 | 1.54-3.25 | <.001 |
| **Statin use** | | | | | | |
| **Yes (*v* no)** | **0.85** | **0.63-1.14** | **.29** | **0.93** | **0.53-1.62** | **.81** |

#### Model 2[2]

| | EFS | | | OS | | |
|---|---|---|---|---|---|---|
| | HR | 95% CI | *P* | HR | 95% CI | *P* |
| Sex | | | | | | |
| Male (*v* female) | 1.35 | 1.13-1.61 | <.001 | 1.47 | 1.01-2.17 | .044 |
| FLIPI | | | | | | |
| (high *v* low) | 1.97 | 1.54-2.52 | <.001 | 4.78 | 2.30-9.94 | <.001 |
| (Intermediate *v* low) | 1.32 | 1.02-1.72 | .034 | 2.48 | 1.14-5.39 | .020 |
| **Statin use** | | | | | | |
| **Yes (*v* no)** | **0.81** | **0.61-1.08** | **0.16** | **1.04** | **0.60-1.80** | **0.87** |

#### Model 3[3]

| | EFS | | | OS | | |
|---|---|---|---|---|---|---|
| | HR | 95% CI | *P* | HR | 95% CI | *P* |
| Age[4] | | | | | | |
| >60 (*v* ≤60) | - | - | - | 1.93 | 1.28-2.90 | .001 |
| Sex | | | | | | |
| Male (*v* female) | 1.39 | 1.15-1.67 | <.001 | 1.82 | 1.20-2.78 | .005 |
| Bone marrow involvement[5] | | | | | | |
| Yes (*v* no) | 1.43 | 1.17-1.75 | <.001 | - | - | - |
| LDH | | | | | | |
| >UNL (*v* ≤UNL) | 1.23 | 1.02-1.50 | .027 | 1.95 | 1.30-2.92 | .001 |
| Hemoglobin, g/dL | | | | | | |
| <12 (*v* ≥12) | 1.62 | 1.29-2.03 | <.001 | 2.46 | 1.57-3.84 | <.001 |
| ß2-microglobulin, mg/L | | | | | | |
| ≥3 (*v* <3) | 1.55 | 1.27-1.89 | <.001 | 1.66 | 1.08-2.54 | .020 |
| Induction arm | | | | | | |
| R-CVP (*v* R-CHOP) | 1.40 | 1.13-1.72 | .001 | 1.57 | 1.00-2.45 | .045 |
| R-FCM (*v* R-CHOP) | 1.00 | 0.61-1.64 | .97 | 4.70 | 2.44-9.03 | <.001 |
| **Statin use** | | | | | | |
| **Yes (*v* no)** | **0.98** | **0.72-1.32** | **.91** | **1.17** | **0.65-2.09** | **.58** |

*Abbreviations: yrs, years; LDH, lactate dehydrogenase; UNL, upper normal limit; FLIPI, follicular lymphoma prognostic index); EFS, event-free survival; OS, overall survival; HR, hazard ratio; CI, confidence interval.*

[1]*imbalanced parameters between patients on or off statin use (with a level set up at P<.1) were incorporated into the model. The model is based on n=1130 patients for both EFS (523 events and 607 censored data) and OS (113 events and 1017 censored data).*

[2]*FLIPI individual parameters were replaced by the FLIPI composite score. The model is based on n=1133 patients for both EFS (526 events and 607 censored data) and OS (114 events and 1019 censored data).*

[3]*a stepwise regression model based on baseline population characteristic and treatment induction was performed with statin use forced into the model. The model is based on n=1018 patients for both EFS (472 events and 546 censored data) and OS (101 events and 917 censored data).*

[4]*Age was retained in the final stepwise regression model for OS but not EFS.*

[5]*Bone marrow involvement was retained in the final stepwise regression model for EFS but not OS.*